Intraperitoneal chemotherapy for ovarian cancer using sustained-release implantable devices

References

• American Cancer Society. What are the key statistics about ovarian cancer? 2016. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html.
   Google Scholar
• Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384:1376–1388.
   PubMed Web of Science ®Google Scholar
• Tropé C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol. 2007;25:2909–2920.
   PubMed Web of Science ®Google Scholar
• Vaughan S, Road C, Ka L, et al. NIH public access. Nat Rev Cancer. 2012;11:719–725.
   Google Scholar
• Goff BA. Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol. 2013;24:83.
   PubMed Web of Science ®Google Scholar
• Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502–516.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Winzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. Obstet Gynecol Surv. 2006;61:240–242.
   Google Scholar
• Chien J, Kuang R, Landen C, et al. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol. 2013;3:1–6.
   PubMedGoogle Scholar
• Morgan RJ Jr., Alvarez RD, Armstrong DK, et al. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008;6:766–794.
   PubMedGoogle Scholar
• Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. Int J Gynaecol Obstet off Organ Int Fed Gynaecol Obstet. 2003;66:184–190.
   Google Scholar
• Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053–1064.
   PubMed Web of Science ®Google Scholar
• Anirban K. Mitra. Ovarian Cancer Metastasis: A Unique Mechanism of Dissemination, Tumor Metastasis. Dr. Ke Xu (Ed.), InTech. 2016. Available from: https://www.intechopen.com/books/tumor-metastasis/ovarian-cancer-metastasis-a-unique-mechanism-of-dissemination
   Google Scholar
• Yeung T, Leung CS, Yip K, Cellular and molecular processes in ovarian cancer metastasis. A Review In The Theme: Cell And Molecular Processes In Cancer Metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444–C456.
   Web of Science ®Google Scholar
• Auer K, Bachmayr-Heyda A, Aust S, et al. Peritoneal tumor spread in serous ovarian cancer-epithelial mesenchymal status and outcome. Oncotarget. 2015;6:17261–17275.
   PubMedGoogle Scholar
• Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. Jama. 1983;250:3072–3076.
   PubMed Web of Science ®Google Scholar
• Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003;22:465–472.
   PubMedGoogle Scholar
• Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer. 2005;5:355–366.
   PubMed Web of Science ®Google Scholar
• Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7(11),925–934.
   Web of Science ®Google Scholar
• Amadori D, Sansoni E, Amadori A. Ovarian cancer: natural history and metastatic pattern. Front Biosci. 1997;2:g8–g10.
   PubMedGoogle Scholar
• Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–428.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Stenvers K. Getting to know ovarian cancer ascites : opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.
   PubMedGoogle Scholar
• Vergara D, Merlot B, Lucot JP, et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 2010;291:59–66.
   PubMed Web of Science ®Google Scholar
• Kipps E, Tan DSP, Kaye SB Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. 2013.
   Google Scholar
• Stanojeviæ Z, Ranèiæ G, Potiæ-Zeèeviæ N, et al. Pathogenesis of malignant ascites in ovarian cancer patients. Arch Oncol. 2004;12:115–118.
   Google Scholar
• Dakwar GR, Shariati M, Willaert W, et al. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — mission possible?. Adv Drug Deliv Rev. 2017;108:13–24.
   PubMed Web of Science ®Google Scholar
• Pradeep S, Kim SW, Wu SY, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014;26:77–91.
   PubMed Web of Science ®Google Scholar
• Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014;290:839–842.
   PubMed Web of Science ®Google Scholar
• Prat J. Abridged republication of FIGO’s staging classification for cancer of the ovary, fallopian tube, and peritoneum. Cancer. 2015;121:3452–3454.
   PubMed Web of Science ®Google Scholar
• Marcus CS, Maxwell GL, Darcy KM, et al. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 2014;5:25–30.
   PubMed Web of Science ®Google Scholar
• Della PC, Tonini G, Pisano C, et al. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer. 2015;34:17–27.
   PubMed Web of Science ®Google Scholar
• Liu PY, Alberts DS, Monk BJ, et al. An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol. 2007;25:3615–3620.
   PubMed Web of Science ®Google Scholar
• Muenzel D, Engels H-P, Bruegel M, et al. Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1. Radiol Oncol. 2012;46:8–18.
   PubMed Web of Science ®Google Scholar
• Thrall MM, DeLoia JA, Gallion H, et al. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007;105:17–22.
   PubMed Web of Science ®Google Scholar
• Shen D-W, Pouliot LM, Hall MD, et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64:706–721.
   PubMed Web of Science ®Google Scholar
• Nolph KD. Peritoneal anatomy and transport physiology. Replace Ren Funct by Dial. Springer, Dordrecht. 1983;440–456.
   Google Scholar
• Healy JC, Reznek RH. The peritoneum, mesenteries and omenta: normal anatomy and pathological processes. Eur Radiol. 1998;8:886–900.
   PubMed Web of Science ®Google Scholar
• Stommel MWJ, Strik C, Van Goor H. Response to pathological processes in the peritoneal cavity-Sepsis, tumours, adhesions, and ascites. Semin Pediatr Surg. 2014;23:331–335.
   PubMed Web of Science ®Google Scholar
• Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Perit. Carcinomatosis Princ. Manag. Cancer Treat. Res. vol 82. Springer, Boston, MA. 1996.
   Google Scholar
• Van der Speeten K, Stuart OA, Sugarbaker PH, et al. Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol. 2009;6(1):72–81.
   PubMedGoogle Scholar
• Baron MA. Structure of the intestinal peritoneum in man. Am J Anat. 1941;69:439–497.
   Google Scholar
• Blake PG, Daugirdas JT. Physiology of Peritoneal Dialysis. Handb Dial, 3rd ed. Kluwer: Lippincott Williams and Wilkins, 2001:281–296.
   Google Scholar
• Flessner MF The transport barrier in intraperitoneal therapy. 2005.
   Google Scholar
• Dobbie JW. Ultrastructure and pathology of the peritoneum in peritoneal dialysis. In The textbook of peritoneal dialysis. Springer, Dordrecht. 1994:17–44.
   Google Scholar
• Flessner MF. Peritoneal transport physiology: insights from basic research. J Am Soc Nephrol. 1991;2:122–135.
   PubMed Web of Science ®Google Scholar
• Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneallu administered compounds. J Pharmacol Exp Ther. 1971;178:562–566.
   PubMed Web of Science ®Google Scholar
• De Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. In Advances in peritoneal surface oncology. Springer, Berlin, Heidelberg.2007;39–51.
   Google Scholar
• Cima MJ et al. Single compartment drug delivery. Journal of Controlled Release. 2014;190:157–171.
   Google Scholar
• Mactier RA, Khanna R. Absorption of fluid and solutes from the peritoneal cavity - Theoretic and therapeutic implications and applications. ASAIO Trans. 1989;35:122–131.
   PubMedGoogle Scholar
• Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst. 1997;89:480–487.
   PubMed Web of Science ®Google Scholar
• Van der Speeten K, Govaerts K, Stuart OA, et al. Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patients. Gastroenterol Res Pract. 2012; Article ID 378064: 9.
   Google Scholar
• Flessner MF, Dedrick RL. Role of the liver in small-solute transport during peritoneal dialysis. J Am Soc Nephrol. 1994;5:116–120.
   PubMed Web of Science ®Google Scholar
• Howell SB. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int J Gynecol Cancer. 2008;18(Suppl 1):20–25.
   PubMedGoogle Scholar
• Dedrick R, Myers C, Bungay P. Pharmacokinetic rationale for peritoneal drug administration. Cancer Treat Rep. 1978;62:1–11.
   PubMedGoogle Scholar
• Markman M. Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer. Crit Rev Oncol Hematol. 2001;38:171–175.
   PubMed Web of Science ®Google Scholar
• De SL, Ceelen W, Remon JP, et al. Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. Sci World J. 2013;2013:7.
   Google Scholar
• Shimada T, Nomura M, Yokogawa K, et al. Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. Jpp. 2005;57:177–181.
   Google Scholar
• Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol. 1993;14:15–28.
   PubMed Web of Science ®Google Scholar
• Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev. 1986;13:219–242.
   PubMed Web of Science ®Google Scholar
• Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the gynecol. J Clin Oncol. 2001;19:1001–1007.
   PubMed Web of Science ®Google Scholar
• Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Winzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;61:240–242.
   Google Scholar
• Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2006;100:27–32.
   PubMed Web of Science ®Google Scholar
• Elit L, Oliver TK, Covens A, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: A systematic review with metaanalyses. Cancer. 2007;109:692–702.
   PubMed Web of Science ®Google Scholar
• NCI. NCI clinical announcement on intraperitoneal chemotherapy in ovarian cancer. 2006. p. 1–22. Available from: www.ctep.cancer.gov.
   Google Scholar
• Helm CW. Ports and complications for intraperitoneal chemotherapy delivery. BJOG Int J Obstet Gynaecol. 2012;119(2):150–159.
   Web of Science ®Google Scholar
• Stampler KM, Holtz DO, Dunton CJ. Reducing excessive toxicity in ovarian cancer treatment: a personalized approach. Futur Oncol. 2011;7:789–798.
   PubMed Web of Science ®Google Scholar
• Makhija S, Leitao M, Sabbatini P, et al. Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol. 2001;81:77–81.
   PubMed Web of Science ®Google Scholar
• Hotouras A, Desai D, Bhan C, et al. Heated IntraPEritoneal Chemotherapy (HIPEC) for patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2016;26:661–670.
   PubMed Web of Science ®Google Scholar
• Ze L, Wang J, Guillaume Wientjes M, et al. Intraperitoneal therapy for peritoneal cancer. Futur Oncol. 2011;6:1625–1641.
   Web of Science ®Google Scholar
• Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol. 2009;16:7–15.
   PubMed Web of Science ®Google Scholar
• Su WH, Ho TY, Li YT, et al. Metronomic therapy for gynecologic cancers. Taiwan J Obstet Gynecol. 2012;51(2):167–178.
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer]. 2004;4:423–436.
   PubMed Web of Science ®Google Scholar
• Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2(12):733–740.
   Google Scholar
• Mutsaers AJ. Metronomic Chemotherapy. Top Companion Anim Med. 2009;24:137–143.
   PubMed Web of Science ®Google Scholar
• Bajaj G, Yeo Y. Drug delivery systems for intraperitoneal therapy. Pharm Res. 2010;27:735–738.
   PubMed Web of Science ®Google Scholar
• Lu Z, Tsai M, Lu D, et al. Tumor penetrating microparticles for intraperitoneal therapy of ovarian cancer. J Pharmacol Exp Ther. 2009;327:673–682.
   Web of Science ®Google Scholar
• Armstrong DK, Fleming GF, Markman M, et al. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer?) in recurrent ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2006;103:391–396.
   PubMed Web of Science ®Google Scholar
• Yang M, Yu T, Wood J, et al. Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model. Drug Deliv Transl Res. 2014 [cited 2017 Oct 11];4:203–209.
   PubMed Web of Science ®Google Scholar
• Kohane DS, Tse JY, Yeo Y, et al. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mater Res Part A. 2006;77:351–361.
   PubMed Web of Science ®Google Scholar
• Deng Y, Yang F, Cocco E, et al. Improved i.p. drug delivery with bioadhesive nanoparticles. Proc Natl Acad Sci. 2016;113:11453–11458.
   PubMed Web of Science ®Google Scholar
• Roby KF, Niu F, Rajewski RA, et al. Syngeneic mouse model of epithelial ovarian cancer: effects of nanoparticulate paclitaxel, Nanotax®. Adv Exp Med Biol. 2008;622:169–181.
   PubMed Web of Science ®Google Scholar
• Williamson SK, Johnson GA, Maulhardt HA, et al. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies. Cancer Chemother Pharmacol. 2015;75:1075–1087.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang JC, Zhang X, et al. A novel mixed micelle gel with thermo-sensitive property for the local delivery of docetaxel. J Control Release. 2009;135:175–182.
   PubMed Web of Science ®Google Scholar
• Bajaj G, Kim MR, Mohammed SI, et al. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release. 2012;158:386–392.
   PubMed Web of Science ®Google Scholar
• Cho EJ, Sun B, Doh KO, et al. Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. Biomaterials. 2015;37:312–319.
   PubMed Web of Science ®Google Scholar
• Sun B, Taha MS, Ramsey B, et al. Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals. J Control Release. 2016;235:91–98.
   PubMed Web of Science ®Google Scholar
• Xie Y, Long Q, Wu Q, et al. Improving therapeutic effect in ovarian peritoneal carcinomatosis with honokiol nanoparticles in a thermosensitive hydrogel composite. RSC Adv. 2012;2:7759.
   Web of Science ®Google Scholar
• Grant J, Blicker M, Piquette-Miller M, et al. Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel. J Pharm Sci. 2005;94:1512–1527.
   PubMed Web of Science ®Google Scholar
• Ho E, Vassileva V, Allen C, et al. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. J Control Release. 2005;104:181–191.
   PubMed Web of Science ®Google Scholar
• Vassileva V, Grant J, De Souza R, et al. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother Pharmacol. 2007;60:907–914.
   PubMed Web of Science ®Google Scholar
• Lim Soo P, Cho J, Grant J, et al. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology. Eur J Pharm Biopharm. 2008;69:149–157.
   PubMed Web of Science ®Google Scholar
• Vassileva V, Moriyama EH, De Souza R, et al. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. Br J Cancer. 2008;99:2037–2043.
   PubMed Web of Science ®Google Scholar
• Ho E, Soo PL, Allen C, et al. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Control Release. 2007;117:20–27.
   PubMed Web of Science ®Google Scholar
• Grant J, Lee H, Soo PL, et al. Influence of molecular organization and interactions on drug release for an injectable polymer-lipid blend. Int J Pharm. 2008;360:83–90.
   PubMed Web of Science ®Google Scholar
• Zahedi P, De Souza R, Piquette-Miller M, et al. Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. Int J Pharm. 2009;377:76–84.
   PubMed Web of Science ®Google Scholar
• De Souza R, Zahedi P, Allen CJ, et al. Biocompatibility of injectable chitosan-phospholipid implant systems. Biomaterials. 2009;30:3818–3824.
   PubMed Web of Science ®Google Scholar
• Zahedi P, Stewart J, De Souza R, et al. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. J Control Release. 2012;158:379–385.
   PubMed Web of Science ®Google Scholar
• Zahedi P, De Souza R, Piquette-Miller M, et al. Docetaxel distribution following intraperitoneal administration in mice. J Pharm Sci. 2011;14:90–99.
   Web of Science ®Google Scholar
• Ye H, Tanenbaum LM, Na YJ, et al. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. J Control Release. 2015;220:358–367.
   PubMed Web of Science ®Google Scholar
• Hamilton CA, Berek JS. Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol. 2006;18:507–515.
   PubMed Web of Science ®Google Scholar
• Mohamed F, Marchettini P, Stuart OA, et al. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol. 2003;52:405–410.
   PubMed Web of Science ®Google Scholar
• Tsai M, Lu Z, Wang J, et al. Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel. Pharm Res. 2007;24:1691–1701.
   PubMed Web of Science ®Google Scholar
• Rao G, Crispens M, Rothenberg ML. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective. J Clin Oncol. 2007;25:2867–2872.
   PubMed Web of Science ®Google Scholar
• Halder J, Kamat AA, Landen CN, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res. 2006;12:4916–4924.
   PubMed Web of Science ®Google Scholar
• Vassileva V, Allen CJ, Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther. 2008;7:630–637.
   PubMed Web of Science ®Google Scholar